Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2018

01-02-2018 | Clinical Trial

The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel

Authors: Rinat Bernstein-Molho, Yael Laitman, Hagit Schayek, Orit Reish, Shira Lotan, Sara Haim, Jamal Zidan, Eitan Friedman

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Background

Hereditary breast cancer is predominantly associated with germline mutations in the BRCA1 or BRCA2 genes. A few recurring mutations in these genes were reported in ethnically diverse Jewish populations. Since 2013, most oncogenetic laboratories in Israel adopted a two-step approach for BRCA1/2 genotyping, where the first step is genotyping for 14 seemingly recurring mutations—first-pass genotyping. The aim of this study was to assess the yield of this targeted BRCA sequencing.

Methods

Clinical and genotyping data of all individuals who underwent oncogenetic counseling and first-pass BRCA genotyping at the Oncogenetic Service Sheba and Assaf Harofeh Medical Centers from 1 February 2013 to 30 June 2017 were reviewed. All study participants were unrelated to each other.

Results

Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers. In 54% of cancer-free carriers, no clinically suspicious family history of cancer was ascertained.

Conclusions

The currently used scheme of first-pass genotyping in Israel seems to have a high yield of mutation detection even in the absence of a significant family history of cancer. The challenge is to optimize the currently used targeted panel of common mutations and adjust it to the accumulating new data in the Israeli population.
Literature
1.
Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241–1247CrossRefPubMed
2.
Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR et al (2000) Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients. Gynecol Oncol 78:148–151CrossRefPubMed
3.
Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T et al (1997) Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1:47–51PubMed
4.
Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A et al (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272–274CrossRefPubMedPubMedCentral
5.
Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bar-Sade RB, Chetrit A et al (2001) The Tyr978X BRCA1 mutation in non-Ashkenazi Jews: occurrence in high-risk families, general population and unselected ovarian cancer patients. Public Health Genomics 4:50–55CrossRef
6.
Laitman Y, Simeonov M, Herskovitz L, Kushnir A, Shimon-Paluch S, Kaufman B et al (2012) Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 133:1153–1157CrossRefPubMed
7.
Sagi M, Eilat A, Avi LB, Goldberg Y, Bercovich D, Hamburger T et al (2011) Two BRCA1/2 founder mutations in Jews of Sephardic origin. Fam Cancer 10:59–63CrossRefPubMed
8.
Laitman Y, Borsthein RT, Stoppa-Lyonnet D, Dagan E, Castera L, Goislard M et al (2011) Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Res Treat 127:489–495CrossRefPubMed
9.
Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158CrossRefPubMedPubMedCentral
10.
11.
Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535–545CrossRefPubMed
12.
Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L et al (2016) The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet 209:50–52CrossRefPubMed
13.
14.
Zick A, Kadouri L, Cohen S, Frohlinger M, Hamburger T, Zvi N et al (2017) Recurrent TP53 missense mutation in cancer patients of Arab descent. Fam Cancer 16:295–301CrossRefPubMed
15.
16.
Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S et al (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14:555–563CrossRefPubMed
17.
18.
Janavičius R (2010) Founder BRCA1/2 mutations in the Europe: implications for hereditary breast–ovarian cancer prevention and control. EPMA J 1:397–412CrossRefPubMedPubMedCentral
19.
Weitzel JN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO, Blazer KR et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297:2587–2595CrossRefPubMed
20.
King M-C, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed
21.
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970CrossRefPubMedPubMedCentral
22.
Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33CrossRefPubMed
Metadata
Title
The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel
Authors
Rinat Bernstein-Molho
Yael Laitman
Hagit Schayek
Orit Reish
Shira Lotan
Sara Haim
Jamal Zidan
Eitan Friedman
Publication date
01-02-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4551-7

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Clinical trial

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial

Clinical trial

Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain

Letter to the Editor

Reclassifying HER2-equivocal disease

Letter to the Editor

Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?

Letter to the Editor

Does the elevation of CAMLs predict metastatic breast cancer patients’ survival?

Letter to the Editor

Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits